Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $279,800.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at $10,133,012.96. The trade was a 2.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00.

Bicara Therapeutics Trading Up 2.8%

Shares of BCAX stock opened at $24.28 on Friday. Bicara Therapeutics Inc. has a 1 year low of $10.30 and a 1 year high of $30.99. The firm’s fifty day moving average price is $26.15 and its two-hundred day moving average price is $21.80. The firm has a market capitalization of $1.61 billion, a P/E ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently made changes to their positions in the company. Deutsche Bank AG lifted its holdings in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after purchasing an additional 1,171 shares during the last quarter. Legal & General Group Plc grew its holdings in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. Mariner LLC increased its position in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after buying an additional 1,902 shares during the period. Invesco Ltd. increased its position in Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after buying an additional 1,962 shares during the period. Finally, Quantinno Capital Management LP lifted its holdings in shares of Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after buying an additional 2,447 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on BCAX shares. Mizuho increased their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Wells Fargo & Company upped their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Finally, Guggenheim assumed coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.